(919) 237-4897 info@t3dtherapeutics.com

Our Mission


A Transformational Approach to Treating Alzheimer’s Disease … and more.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.

T3D-959 is designed as an orally-delivered, once-a-day medicine being evaluated for the treatment of Alzheimer’s disease patients with mild to moderate disease severity, and potentially also for patients with mild cognitive impairment (MCI). The mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) or neurodegenerative disorders via improving dysfunctional brain glucose energy and lipid metabolism which in turn, can address cerebral structural and stress events aberrations.

Innovative Ideas

Treating Alzheimer’s disease as a metabolic disease. T3D-959 is a small molecule new chemical entity designed to treat dysfunctional glucose energy and lipid metabolism.

Advanced Technology

Advanced Technology – T3D-959 is a PPAR delta / gamma dual nuclear receptor agonist, a novel mechanism of action. T3D-959 activates PPAR delta  with 15-fold more potency than PPAR gamma. This combination of delta and gamma activities confers unique biological and safety profiles with the potential to address multiple medical impairments in AD and also, Huntington’s disease.

It's Time for a New Paradigm

Address AD, not as a pyramid of cascading pathologies, but as a feedback loop of 3 key events; (1) metabolic (e.g. glucose energy), (2) structural (e.g. plaques) and (3) stress events (e.g. inflammation) that needs to be broken. Intervention aimed at correcting metabolic events has not been adequately tested.

Clear Results to Date

Multiple efficacy signals and excellent safety profile observed in an exploratory Phase 2a clinical trial in mild to moderate AD patients and evidence of potential disease reversal in an animal model of AD.